Agenus grants 200,000 stock options to director

Agenus Inc. reported that director and officer Jennifer Buell received a grant of stock options covering 200,000 shares of common stock at an exercise price of $7.78 per share.

Rhea-AI Filing Summary

Agenus Inc. reported that director and officer Jennifer Buell received a grant of stock options covering 200,000 shares of common stock at an exercise price of $7.78 per share. The options, expiring on August 5, 2036, were awarded under the 2019 Amended and Restated Equity Incentive Plan and vest over three years, with one-third after the first anniversary of the grant date and the remaining two-thirds in two equal annual installments. Following this grant, Buell holds 200,000 stock options directly.

Insider Trade Summary

Grant/Award: 200,000 shares

Grant/Award 1 txn

Insider Buell Jennifer

Role See Remarks

Type	Security	Shares	Price	Value
Grant/Award	Stock Option F1	200,000	$0.00	$0.00

Holdings After Transaction: Stock Option — 200,000 contracts (Direct)

Footnotes (1)

1. F1. Option awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan, and vest over three (3) years, with one-third (1/3) vesting on the first anniversary of the Grant Date and the remaining two-thirds (2/3) vesting in two equal annual installments thereafter.

Key Figures

Options Granted: 200,000 shares Exercise Price: $7.78 per share Expiration Date: August 5, 2036 +3 more

6 metrics

Options Granted 200,000 shares Stock options on common stock granted to Jennifer Buell

Exercise Price $7.78 per share Exercise price of the newly granted stock options

Expiration Date August 5, 2036 Option term for the granted stock options

Post-Grant Option Holdings 200,000 options Total options held directly by Jennifer Buell after the grant

Initial Vesting Portion 1/3 of options Vests on the first anniversary of the grant date

Remaining Vesting Portion 2/3 of options Vests in two equal annual installments after the first anniversary

Key Terms

2019 Amended and Restated Equity Incentive Plan, exercise price, vesting, Grant Date

4 terms

2019 Amended and Restated Equity Incentive Plan financial

"Option awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan"

exercise price financial

"stock options covering 200,000 shares at an exercise price of $7.78 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"options vest over three years, with one-third after the first anniversary and the rest in installments"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Grant Date financial

"one-third vesting on the first anniversary of the Grant Date"

The grant date is the day a company formally gives an employee or contractor the right to receive stock-based compensation, such as stock options or restricted shares. It matters to investors because it fixes key terms—like the price, the start of the ownership clock, and when the award will affect the company’s financial statements and share count—so it can influence dilution, reported expenses, and potential future selling pressure.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did insider Jennifer Buell receive in this AGEN Form 4 filing?

Jennifer Buell received a grant of 200,000 stock options on Agenus Inc. common stock. These options were awarded under the company’s 2019 Amended and Restated Equity Incentive Plan as part of her role as a director and officer.

What is the exercise price of the options granted to Jennifer Buell at AGEN?

The options granted to Jennifer Buell have an exercise price of $7.78 per share. This is the price she would pay per share to convert the options into Agenus Inc. common stock, subject to vesting and other plan terms.

How do the AGEN stock options granted to Jennifer Buell vest over time?

The 200,000 options vest over three years: one-third on the first anniversary of the grant date, and the remaining two-thirds in two equal annual installments thereafter, consistent with the company’s equity incentive plan.

When do Jennifer Buell’s newly granted AGEN stock options expire?

The stock options granted to Jennifer Buell expire on August 5, 2036. After this expiration date, any unexercised options will lapse and can no longer be exercised for Agenus Inc. common shares.

How many Agenus (AGEN) stock options does Jennifer Buell hold after this grant?

After this grant, Jennifer Buell holds 200,000 stock options directly. This reflects the full amount of the newly awarded options reported, as no prior option holdings are listed in this insider transaction summary.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/07/2026 - 02:08 PM Accepted by SEC EDGAR 08/07/2026 - 02:07 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Buell Jennifer

(Last) (First) (Middle)

C/O AGENUS INC.

3 FORBES ROAD

(Street)

LEXINGTON MASSACHUSETTS 02421

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AGENUS INC [ AGEN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$7.78	08/05/2026		A		200,000		(1)	08/05/2036	Common Stock	200,000	$0.00	200,000	D

Explanation of Responses:

1. Option awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan, and vest over three (3) years, with one-third (1/3) vesting on the first anniversary of the Grant Date and the remaining two-thirds (2/3) vesting in two equal annual installments thereafter.

Remarks:

Chairman of the Executive Counsel

	/s/Melissa Orilall, as Attorney-in-Fact for Jennifer Buell	08/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)